@article{3077132,
    title = "Health-related quality of life and utility outcomes with selinexor in relapsed/refractory diffuse large B-cell lymphoma",
    author = "Shah, J. and Shacham, S. and Kauffman, M. and Daniele, P. and Tomaras, D. and Tremblay, G. and Casasnovas, R.-O. and Maerevoet, M. and Zijlstra, J. and Follows, G. and P Vermaat, J.S. and Kalakonda, N. and Goy, A.H. and Choquet, S. and Den Neste, E.V. and Hill, B.T. and Thieblemont, C. and Cavallo, F. and La Cruz, F.D. and Kuruvilla, J. and Hamad, N. and Bouabdallah, R. and Jäger, U. and Caimi, P. and Gurion, R. and Warzocha, K. and Bakhshi, S. and Sancho, J.M. and Schuster, M. and Egyed, M. and Offner, F. and Vasilakopoulos, T.P. and Samal, P. and Nagy, A. and Ku, M. and Canales Albendea, M.Á.",
    journal = "Future Oncology",
    year = "2021",
    volume = "17",
    number = "11",
    pages = "1295-1310",
    publisher = "Future Medicine Ltd",
    issn = "1479-6694, 1744-8301",
    doi = "10.2217/fon-2020-0946",
    keywords = "selinexor;  hydrazine derivative;  selinexor;  triazole derivative, adult;  aged;  anemia;  cancer growth;  cancer recurrence;  cohort analysis;  controlled study;  diffuse large B cell lymphoma;  European Quality of Life 5 Dimensions questionnaire;  fatigue;  female;  Functional Assessment of Cancer Therapy;  gastrointestinal disease;  health care utilization;  health status;  human;  longitudinal study;  major clinical study;  male;  metabolic disorder;  middle aged;  multiple cycle treatment;  neutropenia;  nutritional disorder;  patient volume;  patient-reported outcome;  phase 2 clinical trial;  priority journal;  quality of life;  Review;  thrombocytopenia;  treatment outcome;  treatment response;  clinical trial;  diffuse large B cell lymphoma;  drug resistance;  pathology;  quality of life;  recurrent disease;  very elderly, Adult;  Aged;  Aged, 80 and over;  Drug Resistance, Neoplasm;  Female;  Humans;  Hydrazines;  Lymphoma, Large B-Cell, Diffuse;  Male;  Middle Aged;  Patient Reported Outcome Measures;  Quality of Life;  Recurrence;  Triazoles",
    abstract = "Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT)-Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT-Lymphoma (p ≤ 0.05), FACT-General (p < 0.05) and EuroQoL five-dimensions five-levels index scores (p < 0.001) beginning in cycle 3. The estimated difference in health state utilities for treatment response and progressive disease was both statistically significant and clinically meaningful (mean difference: 0.07; p = 0.001). Conclusion: In patients with relapsed/refractory diffuse large B-cell lymphoma, objective response to selinexor was associated with HRQoL maintenance, reduction in disease-related HRQoL decrements and higher health utilities. © 2021 Patrick Daniele."
}